International multicenter phase III clinical trials (CS21 and CS21A) (9, 10) and Chinese phase III clinical trials (PANDA) (11) showed that during prostate cancer treatment, compared to the widely used GnRH agonists, degarelix could rapidly reduce testosterone levels to the target level by day 3, significantly improving the survival outcomes of patients without PSA recurrence, and its safety was good. The gene discussed is GNRH1; the disease is prostate carcinoma.